(MENAFN- Golin Mena) The I-ONE Molecular Imaging Center participated in the 2nd International Conference of the Saudi Society of Nuclear Medicine (SSNMMI), held in Jeddah, with the participation of leading experts and specialists from within the Kingdom and abroad.

Mona Al-Radhi, Director of the Center, emphasized that this participation represents a highly valuable opportunity, especially since it is held in Jeddah and brings together top specialists from across the Gulf and the Arab world. She stated:

“I-ONE is the first and only center of its kind in the Western Region that produces radiopharmaceuticals and serves all hospitals along the western coast, from Tabuk in the north to Jazan in the south. I-ONE is also a private center combining both radiopharmaceutical production and positron emission tomography (PET) imaging services under one roof, which is a rare model even globally and represents its main strength. We serve more than 10 governmental and private hospitals and medical centers, either by providing radiopharmaceutical doses or delivering PET imaging services, offering comprehensive nuclear medicine and molecular imaging solutions along the western coast of the Kingdom.”

Regarding safety and quality standards, Al-Radhi explained that all final products undergo rigorous quality testing and calibration according to European standards, in compliance with the Saudi Food and Drug Authority (SFDA) guidelines, to ensure the safety of radiopharmaceuticals before reaching patients.
She added that the Center adheres to the Nuclear and Radiation Regulatory Authority standards to ensure both radiation safety and professional practice within the Center, through the use of shielded production and dispensing units, in addition to employing licensed Radiation Safety Officers (RSOs) and conducting regular staff training to ensure daily compliance with safety procedures.

On his part, Abdullah Al-Hashem, Director of the Radiology Department at I-ONE, discussed his vision for the future of nuclear medicine in the Kingdom, stating:

“The future of nuclear medicine lies in smart personalized medicine, built on three main pillars: transitioning to Theranostics by integrating diagnosis and treatment using targeted radiopharmaceuticals, incorporating Artificial Intelligence (AI) to accelerate and enhance diagnostic accuracy and treatment planning, and achieving strategic self-sufficiency by localizing the production of radiopharmaceuticals. I-ONE plays a pivotal role in this within the framework of Vision 2030, serving as a successful model for Jeddah-based companies linking academic research to national healthcare needs.”

Al-Hashem also revealed that the Center is adopting new projects and technologies to expand its diagnostic capabilities, including:

“Expanding the portfolio of diagnostic radiopharmaceuticals beyond F-18 FDG, dedicated to advanced molecular imaging for diseases such as Alzheimer’s and cardiac conditions, providing the healthcare system with faster and more precise diagnostic tools.”

MENAFN06112025005513012199ID1110303538